Evidence Based Review of Management of Cardiorenal Syndrome Type 1

Overview

Journal World J Methodol

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2021 Jul 29

PMID 34322368

Citations 3

Authors

Leong Tung Ong

Affiliations

Soon will be listed here.

Abstract

Cardiorenal syndrome (CRS) type 1 is the development of acute kidney injury in patients with acute decompensated heart failure. CRS often results in prolonged hospitalization, a higher rate of rehospitalization, high morbidity, and high mortality. The pathophysiology of CRS is complex and involves hemodynamic changes, neurohormonal activation, hypothalamic-pituitary stress reaction, inflammation, and infection. However, there is limited evidence or guideline in managing CRS type 1, and the established therapeutic strategies mainly target the symptomatic relief of heart failure. This review will discuss the strategies in the management of CRS type 1. Six clinical studies have been included in this review that include different treatment strategies such as nesiritide, dopamine, levosimendan, tolvaptan, dobutamine, and ultrafiltration. Treatment strategies for CRS type 1 are derived based on the current literature. Early recognition and treatment of CRS can improve the outcomes of the patients significantly.

Citing Articles

Cardiovascular Consequences of Acute Kidney Injury: Treatment Options.

Voicehovska J, Trumpika D, Voicehovskis V, Bormane E, Busmane I, Grigane A Biomedicines. 2023; 11(9).

PMID: 37760806 PMC: 10526099. DOI: 10.3390/biomedicines11092364.

Levosimendan Administration May Provide More Benefit for Survival in Patients with Non-Ischemic Cardiomyopathy Experiencing Acute Decompensated Heart Failure.

Lee W, Wu P, Fang H, Fang Y, Chen H, Tong M J Clin Med. 2022; 11(14).

PMID: 35887759 PMC: 9322737. DOI: 10.3390/jcm11143997.

Risk Factors and Outcome Variables of Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients.

She C, Deng Y, Huang G, Cheng C, Zhang F Int J Gen Med. 2022; 15:1565-1573.

PMID: 35210828 PMC: 8857974. DOI: 10.2147/IJGM.S350361.

References

Pataricza J, Krassoi I, Hohn J, Kun A, Papp J . Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther. 2003; 17(2):115-21. DOI: 10.1023/a:1025331617233. View

Mentz R, Stevens S, DeVore A, Lala A, Vader J, AbouEzzeddine O . Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 2014; 3(2):97-107. PMC: 4324057. DOI: 10.1016/j.jchf.2014.09.003. View

Hauptman P, Swindle J, Burroughs T, Schnitzler M . Resource utilization in patients hospitalized with heart failure: insights from a contemporary national hospital database. Am Heart J. 2008; 155(6):978-985.e1. DOI: 10.1016/j.ahj.2008.01.015. View

Bart B, Goldsmith S, Lee K, Givertz M, OConnor C, Bull D . Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012; 367(24):2296-304. PMC: 3690472. DOI: 10.1056/NEJMoa1210357. View

Hillege H, Girbes A, de Kam P, Boomsma F, de Zeeuw D, Charlesworth A . Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000; 102(2):203-10. DOI: 10.1161/01.cir.102.2.203. View

Owan T, Chen H, Frantz R, Karon B, Miller W, Rodeheffer R . The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail. 2008; 14(4):267-75. PMC: 2424167. DOI: 10.1016/j.cardfail.2007.12.002. View

Verbrugge F, Grieten L, Mullens W . Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med. 2015; 4(3-4):176-88. PMC: 4299260. DOI: 10.1159/000366168. View

Kumar U, Wettersten N, Garimella P . Cardiorenal Syndrome: Pathophysiology. Cardiol Clin. 2019; 37(3):251-265. PMC: 6658134. DOI: 10.1016/j.ccl.2019.04.001. View

Packer M, Colucci W, Fisher L, Massie B, Teerlink J, Young J . Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2014; 1(2):103-11. DOI: 10.1016/j.jchf.2012.12.004. View

10.

Felker G, OConnor C . Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001; 142(3):393-401. DOI: 10.1067/mhj.2001.117606. View

11.

Geisberg C, Butler J . Addressing the challenges of cardiorenal syndrome. Cleve Clin J Med. 2006; 73(5):485-91. DOI: 10.3949/ccjm.73.5.485. View

12.

McLean A, Huang S, Nalos M, Ting I . Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol. 2005; 46(6):830-5. DOI: 10.1097/01.fjc.0000189076.71730.f1. View

13.

Marumo R, Kaizuma S, Nogae S, Kanazawa M, Kimura T, Saito T . Differential upregulation of rat Na-K-Cl cotransporter, rBSC1, mRNA in the thick ascending limb of Henle in different pathological conditions. Kidney Int. 1998; 54(3):877-88. DOI: 10.1046/j.1523-1755.1998.00051.x. View

14.

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M . 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):1810-52. DOI: 10.1161/CIR.0b013e31829e8807. View

15.

Ronco C, Haapio M, House A, Anavekar N, Bellomo R . Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52(19):1527-39. DOI: 10.1016/j.jacc.2008.07.051. View

16.

Wang D, Dowling T, Meadows D, Ayala T, Marshall J, Minshall S . Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004; 110(12):1620-5. DOI: 10.1161/01.CIR.0000141829.04031.25. View

17.

Costanzo M, Guglin M, Saltzberg M, Jessup M, Bart B, Teerlink J . Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007; 49(6):675-83. DOI: 10.1016/j.jacc.2006.07.073. View

18.

Ljungman S, Kjekshus J, Swedberg K . Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992; 70(4):479-87. DOI: 10.1016/0002-9149(92)91194-9. View

19.

Billings 4th F, Shaw A . Clinical trial endpoints in acute kidney injury. Nephron Clin Pract. 2014; 127(1-4):89-93. PMC: 4480222. DOI: 10.1159/000363725. View

20.

Hillege H, Nitsch D, Pfeffer M, Swedberg K, McMurray J, Yusuf S . Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113(5):671-8. DOI: 10.1161/CIRCULATIONAHA.105.580506. View